Innate Pharma Announces First DSMB Review of Ongoing EffiKIR Phase II Trial with lirilumab

Innate Pharma SA (OTC: IPHYF), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the Data and Safety Monitoring Board ("DSMB") completed its first assessment of the EffiKIR study and unanimously recommended continuation of the trial without modification. The assessment was based on a safety